Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | February 09, 2026 | February 12, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Chief Commercial Officer | January 05, 2021 | January 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date February 09, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,619 |
Reported balance
After 2026-02-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 10,690 · Balance 45,619 F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 29,484 shares of common stock owned by the Reporting Person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.37 · Expires 2036-02-09 | Direct | 17,730 |
Reported balance
After 2026-02-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-09 · Grant · Acquired 17,730 · Balance 17,730 F3: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.
F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 29,484 shares of common stock owned by the Reporting Person.
F3: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
bluebird bio, Inc.
Report date January 05, 2021 · Filed January 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,103 |
Ending reported balance
After 2021-01-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-01-05 · Sale · Disposed 40 · Balance 26,917 F1: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2: The range in prices for the transaction reported on this line was $44.71 to $45.09. The average weighted price was $44.9522. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2021-01-06 · Sale · Disposed 1,055 · Balance 25,862 F1: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3: The range in prices for the transaction reported on this line was $44.25 to $45.24. The average weighted price was $44.7586. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2021-01-06 · Sale · Disposed 759 · Balance 25,103 F1: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F4: The range in prices for the transaction reported on this line was $45.25 to $45.83. The average weighted price was $45.4635. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
F2: The range in prices for the transaction reported on this line was $44.71 to $45.09. The average weighted price was $44.9522. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The range in prices for the transaction reported on this line was $44.25 to $45.24. The average weighted price was $44.7586. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The range in prices for the transaction reported on this line was $45.25 to $45.83. The average weighted price was $45.4635. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Decibel Therapeutics, Inc.
Report date September 25, 2023 · Filed September 25, 2023
Section 16 reporting ended · disclosed 2023-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 1
1 source rowRow 1 · 2023-09-25 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3: Includes 5,000 unvested Company RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2032-06-16 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2033-06-12 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-25 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.20 · Expires 2031-12-02 | Direct | 0 |
Reported balance
After 2023-09-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-25 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment and less than the sum of the amount of the Cash Consideration, the amount of the DB-OTO Milestone Payment and the amount of the Registration Study Milestone Payment (each a "Tranche 3 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 3 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 3 Option, the Registration Study Milestone Payment is equal to the excess of $7.50 over the exercise price per share with respect to such Tranche 3 Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"),
F2: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU.
F3: Includes 5,000 unvested Company RSUs.
F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time.
F5: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR.
F6: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment and less than the sum of the amount of the Cash Consideration, the amount of the DB-OTO Milestone Payment and the amount of the Registration Study Milestone Payment (each a "Tranche 3 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 3 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 3 Option, the Registration Study Milestone Payment is equal to the excess of $7.50 over the exercise price per share with respect to such Tranche 3 Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (Right to Buy) · Derivative | 17,730 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001140361-26-004888 · form4.xml · derivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,730 Underlying: Common Stock · 17,730 shares Expires 2036-02-09 F3 · derivative.exercise_date: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-004888 · form4.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,619 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 29,484 shares of common stock owned by the Reporting Person. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 16,279 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001140361-25-005537 · form4.xml · derivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,279 Underlying: Common Stock · 16,279 shares Expires 2035-02-19 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005537 · form4.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,929 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 12,020 RSUs granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (iii) 12,020 shares of common stock owned by the Reporting Person. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 37,541 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001140361-24-010242 · form4.xml · derivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,541 Underlying: Common Stock · 37,541 shares Expires 2034-02-26 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 24,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-010242 · form4.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,040 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1). Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 16:29 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $6.20 | Not disclosed |
DisclosureSEC source: 0000899243-23-019496 · doc4.xml · derivative · entry 4 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2031-12-02 F6 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment and less than the sum of the amount of the Cash Consideration, the amount of the DB-OTO Milestone Payment and the amount of the Registration Study Milestone Payment (each a "Tranche 3 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 3 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 3 Option, the Registration Study Milestone Payment is equal to the excess of $7.50 over the exercise price per share with respect to such Tranche 3 Option. F6 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment and less than the sum of the amount of the Cash Consideration, the amount of the DB-OTO Milestone Payment and the amount of the Registration Study Milestone Payment (each a "Tranche 3 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 3 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 3 Option, the Registration Study Milestone Payment is equal to the excess of $7.50 over the exercise price per share with respect to such Tranche 3 Option. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 16:29 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | Not disclosed Strike: $4.78 | Not disclosed |
DisclosureSEC source: 0000899243-23-019496 · doc4.xml · derivative · entry 3 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2033-06-12 F5 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. F5 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a "Tranche 2 Option") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 16:29 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.30 | Not disclosed |
DisclosureSEC source: 0000899243-23-019496 · doc4.xml · derivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-06-16 F4 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a "Tranche 1 Option"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time. Read SEC document |
| September 25, 2023 Filed Sep 25, 2023 16:29 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | Disposition to issuerCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-019496 · doc4.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2 · shares: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. F3 · shares: Includes 5,000 unvested Company RSUs. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. ("Parent") and Symphony Acquisition Sub, Inc. ("Purchaser"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"), F2 · price: (Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the "CVR Agreement"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a "Company RSU"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:40 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0000950170-23-027992 · ownership.xml · derivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-06-12 F3 · derivative.exercise_date: This option was granted on June 13, 2023 for 5,000 shares. The shares underlying the option are scheduled to vest in full on the one year anniversary of the date of grant of the option (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the option), subject to the reporting person's continued service. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:40 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027992 · ownership.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Consists of shares of the Issuer's common stock issuable under 5,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest in full on the one year anniversary of the date of grant of the RSUs (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the RSUs), subject to the reporting person's continued service. F2 · balance_after: Includes 5,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 18:55 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0000899243-22-023471 · doc4.xml · derivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option was granted on June 17, 2022 for 10,000 shares. The shares underlying the option are scheduled to vest in full on the one year anniversary of the date of grant of the option (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the option), subject to the reporting person's continued service. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 16:17 UTC | Decibel Therapeutics, Inc. DBTX · Entity 109458 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0000899243-21-046951 · doc4.xml · derivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-12-02 F1 · derivative.exercise_date: The option was granted on December 3, 2021 for 20,000 shares. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 17:57 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 759 | $45.46 | $34,506.80 |
DisclosureSEC source: 0001562180-21-000267 · primarydocument.xml · nonDerivative · entry 3 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,103 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F4 · price: The range in prices for the transaction reported on this line was $45.25 to $45.83. The average weighted price was $45.4635. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 17:57 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,055 | $44.76 | $47,220.32 |
DisclosureSEC source: 0001562180-21-000267 · primarydocument.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,862 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $44.25 to $45.24. The average weighted price was $44.7586. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2021 Filed Jan 8, 2021 17:57 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 40 | $44.95 | $1,798.09 |
DisclosureSEC source: 0001562180-21-000267 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,917 F1 · kind: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $44.71 to $45.09. The average weighted price was $44.9522. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:48 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1 | $46.50 | $46.50 |
DisclosureSEC source: 0001562180-20-007082 · primarydocument.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,957 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:48 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 35 | $46.19 | $1,616.63 |
DisclosureSEC source: 0001562180-20-007082 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,958 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $45.48 to $46.37. The average weighted price was $46.1895. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 4 | $54.43 | $217.74 |
DisclosureSEC source: 0001562180-20-006548 · primarydocument.xml · nonDerivative · entry 3 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,993 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F4 · price: The range in prices for the transaction reported on this line was $54.33 to $54.48. The average weighted price was $54.4340. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 7 | $53.83 | $376.79 |
DisclosureSEC source: 0001562180-20-006548 · primarydocument.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,997 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $53.28 to $54.10. The average weighted price was $53.8272. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 24 | $52.51 | $1,260.21 |
DisclosureSEC source: 0001562180-20-006548 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,004 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $52.25 to $53.08. The average weighted price was $52.5087. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 36 | $52.77 | $1,899.54 |
DisclosureSEC source: 0001562180-20-006303 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,028 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $52.48 to $53.09. The average weighted price was $52.765. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: 1 share was acquired under the bluebird bio, Inc. employee stock purchase plan. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 16:08 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 35 | $58.60 | $2,051.06 |
DisclosureSEC source: 0001562180-20-005923 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,063 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $58.468 to $58.77. The average weighted price was $58.6018. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 9 | $60.98 | $548.83 |
DisclosureSEC source: 0001562180-20-005310 · primarydocument.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,098 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $60.83 to $61.00. The average weighted price was $60.9811. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:05 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 26 | $60.32 | $1,568.27 |
DisclosureSEC source: 0001562180-20-005310 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,107 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $59.75 to $60.72. The average weighted price was $60.3182. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 17:16 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 36 | $61.57 | $2,216.62 |
DisclosureSEC source: 0001562180-20-005056 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,133 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $61.27 to $61.88. The average weighted price was $61.5728. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 17:44 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 27 | $64.24 | $1,734.57 |
DisclosureSEC source: 0001562180-20-004287 · primarydocument.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,169 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $63.76 to $64.30. The average weighted price was $64.2432. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 17:44 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 8 | $63.36 | $506.90 |
DisclosureSEC source: 0001562180-20-004287 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,196 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $62.76 to $63.57. The average weighted price was $63.3626. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 1,361 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-003357 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,204 F1 · security: Restricted stock units for common stock to vest on a monthly basis over a 12-month period with a vesting commencement date on May 1, 2020. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:19 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $73.84 | $0.00 |
DisclosureSEC source: 0001562180-20-002155 · primarydocument.xml · derivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-03-02 F3 · derivative.exercise_date: This option vests over a four-year period, at a rate of 25% on 01/04/2021 and in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:19 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002155 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,843 F1 · security: Restricted stock unit awards vest over a four-year period at the rate of 25% on 01/04/2021, 25% on 01/04/2022, 25% on 01/04/2023, and 25% on 01/04/2024. F2 · balance_after: 195 shares were acquired under the bluebird bio, Inc. employee stock purchase plan. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 17:33 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 1,049 | $89.97 | $94,379.79 |
DisclosureSEC source: 0001562180-20-000310 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,148 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $89.50 to $90.42. The average weighted price was $89.9712. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 17:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 517 | $84.96 | $43,924.11 |
DisclosureSEC source: 0001562180-20-000278 · primarydocument.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,197 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $84.70 to $85.07. The average weighted price was $84.9596. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: 33 shares were acquired under the bluebird bio, Inc. employee stock purchase plan. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 18:42 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $134.63 | $0.00 |
DisclosureSEC source: 0001209191-19-007510 · doc4.xml · derivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-02-01 F3 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2020 and in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 18:42 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007510 · doc4.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,681 F1 · security: Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2020, 25% on 01/04/2021, 25% on 01/04/2022, and 25% on 01/04/2023. F2 · balance_after: 133 shares were acquired under the bluebird bio, Inc. employee stock purchase plan on January 31, 2019. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 219 | $114.30 | $25,032.69 |
DisclosureSEC source: 0001209191-19-003077 · doc4.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,548 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $114.00 to $114.72. The average weighted price was $114.3045. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 16:53 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 424 | $113.29 | $48,034.88 |
DisclosureSEC source: 0001209191-19-003077 · doc4.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,767 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $112.73 to $113.70. The average weighted price was $113.2898. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 16:39 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 115 | $100.32 | $11,536.80 |
DisclosureSEC source: 0001209191-19-002552 · doc4.xml · nonDerivative · entry 3 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,239 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 16:39 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 205 | $99.27 | $20,351.05 |
DisclosureSEC source: 0001209191-19-002552 · doc4.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,354 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $99.08 to $99.805. The average weighted price was $99.2734. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 16:39 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 108 | $98.31 | $10,617.93 |
DisclosureSEC source: 0001209191-19-002552 · doc4.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,559 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $98.07 to $98.845. The average weighted price was $98.3142. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2019 Filed Jan 9, 2019 16:48 UTC Amendment | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 128 | $100.32 | $12,840.96 |
DisclosureSEC source: 0001209191-19-003072 · doc4a.xml · nonDerivative · entry 3 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,191 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. Read SEC document |
| January 03, 2019 Filed Jan 9, 2019 16:48 UTC Amendment | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 228 | $99.27 | $22,634.04 |
DisclosureSEC source: 0001209191-19-003072 · doc4a.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,319 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F3 · price: The range in prices for the transaction reported on this line was $99.08 to $99.805. The average weighted price was $99.2721. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 03, 2019 Filed Jan 9, 2019 16:48 UTC Amendment | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 120 | $98.32 | $11,797.86 |
DisclosureSEC source: 0001209191-19-003072 · doc4a.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,547 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · price: The range in prices for the transaction reported on this line was $98.07 to $98.845. The average weighted price was $98.3155. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 06:32 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 100 | $158.10 | $15,810.00 |
DisclosureSEC source: 0001209191-18-047884 · doc4.xml · nonDerivative · entry 2 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,667 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes 87 shares that were acquired by the Reporting Person under the bluebird bio, Inc. employee stock purchase plan on July 31, 2018. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 06:32 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 159 | $158.05 | $25,129.95 |
DisclosureSEC source: 0001209191-18-047884 · doc4.xml · nonDerivative · entry 1 FINGER ALISON CECILY · CIK 0001731164 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,767 F1 · shares: Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units. F2 · balance_after: Includes 87 shares that were acquired by the Reporting Person under the bluebird bio, Inc. employee stock purchase plan on July 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.